Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects
Latest Information Update: 26 Aug 2023
At a glance
- Drugs Lamivudine/abacavir (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections; HIV-1 infections
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms ASSERT
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 04 May 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 15 Oct 2010 Bone density and turnover results have been published in HIV/AIDS.
- 03 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.